Influence of lamotrigine on progression of early Huntington disease: A randomized clinical trial

Neurology

Volumn 53, Issue 5, 1999, Pages 1000-1011

  Kremer, B ^d   Clark, C M ^a   Almqvist, E W ^d   Raymond, L A ^a   Graf, P ^a   Jacova, C ^a   Mezei, M ^a   Hardy, M A ^d   Snow, B ^a,b   Martin, W ^c   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY OF ALBERTA   (Canada)

^d NONE

Author keywords

Drug trial; Huntington disease; Indices of progression; Lamotrigine; PET

Indexed keywords

AMINO ACID; FLUORODEOXYGLUCOSE; GLUTAMIC ACID; LAMOTRIGINE;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0033595502     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.5.1000     Document Type: Article

References (45)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72: 971-983.
2. Gutekunst CA, Levey A, Heilman C, et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci USA 1995;92:8710-8714.
3. Vonsattel J, Myers R, Stevens T, Ferrante R, Bird E, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577.
4. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976;263:517-519.
5. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976; 263:244-246.
6. Beal MF, Kowall N, Ellison D, Mazurek M, Swartz K, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986;321:168-171.
7. Beal MF, Ferrante R, Swartz K, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991;11:1649-1659.
8. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4192.
9. Greene JG, Porter R, Eller R, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an "excito-toxic" lesion in rat striatum. J Neurochem 1993;61:1151-1154.
10. McGeer EG, Zhu SG. Lamotrigine protects against kainate but not ibotenate lesions in rat striatum. Neurosci Lett 1990; 112:348-351.
11. Schulz JB, Matthews R, Henshaw D, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 1996;71:1043-1048.
12. Dure LS, Young A, Penney JB. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann Neurol 1991;30:785-793.
13. Albin RL, Young A, Penney J, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 1990; 322:1293-1298.
14. Goa KL, Ross S, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-176.
15. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-1335.
16. Shoulson I, Kurlan R, Rubin A, et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: Munsat T, ed. Quantification of neurological deficit. Stoneham, MA: Butterworths, 1989: 271-284.
17. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11: 136-142.
18. Folstein SE, Jensen B, Leigh RJ, Folstein M. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol 1983;5:605-609.
19. Kremer B, Goldberg P, Andrew S, et al. A worldwide study of the Huntington's disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330: 1401-1406.
20. Bruland O, Almqvist EW, Goldberg YP, Boman H, Hayden MR, Knappskog PM. Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence specific internal DNA standard. Clin Genet 1999;55:198-202.
21. Clark CM, Kremer B, Hayden MR. Regional cerebral glucose metabolism in Huntington's disease: a statistical investigation. Human Brain Mapping 1994;2:95-102.
22. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
23. Huang S, Phelps M, Hoffman E, Sideris K, Selin C, Kuhl D. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980;238:E69-E82.
24. Brooks R. Alternative formula for glucose utilization using labelled deoxyglucose. J Nucl Med 1982;23:538-539.
25. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259.
26. Palfi S, Riche D, Brouillet E, et al. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp Neurol 1997;146:135-141.
27. Waldmeier PC, Baumann P, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995;45:1907-1913.
28. Wang SJ, Huang C, Hsu K, Tsai J, Gean PW. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Synapse 1996;24:248-255.
29. 2+ currents in cortical neurons: functional implications. Eur J Pharmacol 1996;307:113-116.
30. Shuaib A, Mahmood R, Wishart T, et al. Neuroprotective effects of lamotrigine in global ischemia in gerbils: a histological, in vivo microdialysis and behavioral study. Brain Res 1995;702:199-206.
31. Casanovas A, Ribera J, Hukkanen M, Riveros-Moreno V, Esquerda JE. Prevention by lamotrigine, MK-801 and N omega-nitro-L-arginine methyl ester of motorneuron cell death after neonatal axotomy. Neuroscience 1996;71:313-325.
32. Connop BP, Boegman R, Beninger R, Jhamandas K. Malonate-induced degeneration of basal forebrain cholinergic neurons: attenuation by lamotrigine, MK-801, and 7-nitroindazole. J Neurochem 1997;68:1191-1199.
33. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group. N Engl J Med 1994;330:585-591.
34. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-1431.
35. Stefani A, Spadoni F, Bernardi G. Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 1997;147:115-122.
36. Mayeux R, Stern Y, Herman A, Greenbaum L, Fahn S. Correlates of early disability in Huntington's disease. Ann Neurol 1986;20:727-731.
37. Kieburtz K, MacDonald M, Shih C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 1994;31:872-874.
38. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995;10:211-214.
39. Illarioshkin SN, Igarashi S, Onodera O, et al. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann Neurol 1994;36:630-635.
40. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394-399.
41. 18FDG and computed tomographic scan. Ann Neurol 1982;12:425-434.
42. Hayden MR, Martin WRW, Stoessl AJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986;36:888-894.
43. Young AB, Penney JB, Starosta-Rubinstein S, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986;20:296-303.
44. Grafton ST, Mazziotta JC, Pahl JJ, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992:49:1161-1167.
45. Mazziotta JC, Phelps ME, Plummer D, Kuhl DE. Quantitation in positron emission computed tomography: 5. Physical-anatomical effects. J Comput Assist Tomogr 1981;5:734-743.